Pharmaceuticals Japan

Japan ADHD Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Japan ADHD Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Type, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Japan · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.33 Bn Placeholder estimate
Estimate 2025 $1.42 Bn 7% of the global market
Projected 2034 $2.52 Bn 77.8% Adds $1.10 Bn over 9 forecast years
CAGR 2025–2034 6.6% Faster than 26% of 180 Pharmaceuticals markets here
Key players 5
  • Japan is 7% of the global market.
  • In APAC, the largest is China at $1.47 Bn.
  • Fastest growing: India at 8.6% a year.
  • Japan ranks 2nd of 10 by size in APAC.

Market size projection

Japan

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.10 Bn total, 2026–2034

Year-by-year market size, 2024–2034
ADHD Drugs Market market size by year, Japan
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.33 Bn — —
2025 (base) $1.42 Bn +$87.7 Mn —
2026 (forecast) $1.51 Bn +$93.5 Mn +6.6%
2027 (forecast) $1.61 Bn +$99.6 Mn +13.6%
2028 (forecast) $1.72 Bn +$106.2 Mn +21.1%
2029 (forecast) $1.83 Bn +$113.2 Mn +29.1%
2030 (forecast) $1.95 Bn +$120.7 Mn +37.7%
2031 (forecast) $2.08 Bn +$128.6 Mn +46.7%
2032 (forecast) $2.21 Bn +$137.1 Mn +56.4%
2033 (forecast) $2.36 Bn +$146.2 Mn +66.7%
2034 (forecast) $2.52 Bn +$155.8 Mn +77.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $20.22 Bn
  2. North America $10.94 Bn
  3. US $7.91 Bn
  4. APAC $4.77 Bn
  5. Europe $3.91 Bn
  6. Canada $1.63 Bn
  7. China $1.47 Bn
  8. Japan (this report) $1.42 Bn
  9. Latin America $958.3 Mn
  10. Middle East $779.6 Mn
  11. Germany $640.2 Mn
  12. Brazil $567.3 Mn
  13. France $516.4 Mn
  14. Italy $493.5 Mn
  15. UK $454.8 Mn
  16. Ecuador $424.6 Mn
  17. Spain $397.3 Mn
  18. India $423.4 Mn
  19. Saudi Arabia $357.4 Mn
  20. Mexico $339.8 Mn
  21. Africa $295.0 Mn
  22. Australia $249.4 Mn
  23. New Zealand $228.5 Mn
  24. Russia $211.1 Mn
  25. South Africa $151.2 Mn
  26. UAE $112.5 Mn
  27. Egypt $57.9 Mn
  28. Philippines $50.5 Mn
  29. Hong Kong $33.7 Mn
  30. Malaysia $28.1 Mn
  31. Singapore $23.2 Mn
  32. Thailand $22.5 Mn
  33. Kenya $12.7 Mn

Report snapshot

Japan ADHD Drugs Market Analysis at a glance
Market size, 2025$1.42 Bn placeholder estimate
Forecast, 2034$2.52 Bn placeholder estimate
Growth (CAGR), 2025–20346.6% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledAttention Deficit Hyperactivity Disorder (ADHD) Drugs
SegmentsDrug type, age and end user (see all)
Key playersTakeda Pharmaceutical Company Ltd, Johnson & Johnson, Novartis AG, Supernus Pharmaceuticals, Teva Pharmaceutical (see all)
Regulator in JapanPMDASource: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
Active clinical trials5 in JapanSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Japan ADHD Drugs Market Analysis Executive Summary

ADHD drugs treat attention deficit hyperactivity disorder in children and adults with stimulant and non-stimulant medicines.

Key segments of the ADHD Drugs market include drug type (Stimulants and Non-Stimulants) and age (Children, Adolescents and Adults).

Bar chart: Japan ADHD Drugs market size, 2024–2034, placeholder estimates. $1.33 Bn in 2024, $1.42 Bn in 2025 and $2.52 Bn in 2034, 6.6% CAGR.
Japan ADHD Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Japan ADHD Drugs Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the ADHD Drugs market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the ADHD Drugs market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the ADHD Drugs market.

Competitive Landscape for ADHD Drugs Market in Japan

The ADHD Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for ADHD Drugs Market in Japan

ADHD Drugs in Japan: rules, payment and research

Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW).⁠[1] Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices).⁠[2] ClinicalTrials.gov lists 5 studies on ADHD Drugs that are recruiting, active or about to start in Japan.⁠[3] Suicide rate: 16.5 per 100,000 people in 2023, the latest WHO figure for Japan.⁠[4]

[1] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[2] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.

[4] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for ADHD Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Japan.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in ADHD Drugs right now, from free public sources.

Clinical trials

5 active trials in Japan

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Otsuka Holdings Co Ltd 4 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Supernus Pharmaceuticals 2 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Axsome Therapeutics 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 40 papers since 2021 (worldwide)

  1. AD-Smart: Alzheimer's trial will test diabetes and ADHD drugs on patients. BMJ (Clinical research ed.), 2026
  2. Regional Variation in ADHD Treatment and Diagnosis Among Children and Adolescents in Denmark. Basic & clinical pharmacology & toxicology, 2026
  3. Detrimental effects of atomoxetine on visual signal detection in rats: comparison with ADHD psychomotor stimulant drugs. Psychopharmacology, 2026
  4. The influence of existing interventions on sleep of youth with attention-deficit/hyperactivity disorder: A meta-analysis of randomized controlled trials. Sleep medicine reviews, 2026
  5. Prescribing trends and spontaneous reporting patterns of adverse drug reactions of ADHD medications in children and adolescents in germany: A retrospective analysis (2013-2022). European child & adolescent psychiatry, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

ADHD Drugs in context

Japan compared

  • Suicide rate: 16.5 per 100,000 people (2023). World: 9.2 per 100,000 people (2023). Highest of the 15 countries we cover in APAC.[1]
  • Health spending per person: 3,638 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 15 countries we cover in APAC.[2]
  • Doctors: 2.65 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 5th highest of the 15 countries we cover in APAC.[3]

[1] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the ADHD Drugs market in Japan?
Placeholder estimate: about $1.42 Bn in 2025, rising to about $2.52 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the ADHD Drugs market in Japan growing?
Placeholder estimate: about 6.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the ADHD Drugs market report cover?
The report splits the market by drug type (Stimulants, Non-Stimulants), age (Children, Adolescents, Adults) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the ADHD Drugs market?
Key players include Takeda Pharmaceutical Company Ltd, Johnson & Johnson, Novartis AG, Supernus Pharmaceuticals and Teva Pharmaceutical.
What is driving the ADHD Drugs market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the ADHD Drugs market. Governments and employers are investing more in mental health care.
Who regulates ADHD Drugs in Japan?
Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW). Source: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
How is healthcare paid for in Japan?
Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices). Source: Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
How many clinical trials on ADHD Drugs are running in Japan?
5 studies are recruiting, active or about to start in Japan, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
What does WHO report for Japan?
Suicide rate: 16.5 per 100,000 people in 2023, the latest WHO figure. Source: WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.
How many people in Japan are 65 or older?
30.0% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 15 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about ADHD Drugs in Japan? Our analysts can size it for your plan. Talk to us See the public data Suicide rate for every country, free. Open the Public Health Dashboard

From our blog

Adaptogens: Ancient Herbs, Modern Market170 WHO Member States report the use of traditional medicine. Adaptogens like ashwagandha, rhodiola and… Stress and Mood Supplements: Ashwagandha and BeyondDepression and anxiety cost the world about US$1 trillion a year. Ashwagandha has some evidence for stress… Antidepressants: Demand, Access and New ApproachesAbout 322 million people live with depression. Treatment works, but most people still do not get it.
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Japan

See all
Same topic, other categories

Related on mental health

See the topic